A new concentrate of clotting factors II, VII, IX and X, made from pooled human plasma collected in citrate anticoagulant by a process involving the adsorption of the effluent from Cohn fraction I on ...
CSL Behring announced that the FDA has approved an expansion of the indication for Corifact (Factor XIII concentrate [human]) infusion, to include the peri-operative management of surgical bleeding in ...
CSL Behring announced that Corifact (factor XIII concentrate [human] injection) has been approved for the routine prophylactic treatment of congenital factor XIII deficiency. Corifact is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results